Italia markets closed

Cingulate Inc. (CING)

NasdaqCM - NasdaqCM Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,8801+0,0148 (+1,71%)
Alla chiusura: 04:00PM EDT
Schermo intero
Caricamento grafico interattivo in corso...
  • GlobeNewswire

    Cingulate Inc. to Present at the LD Micro Main Event XVI

    Presentation on Wednesday, October 4th at 02:30 PM PTKANSAS CITY, Kan., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that Chairman & CEO, Shane J. Schaffer, will be presenting a company overview at the 16th annual Main Event on Wednesday, October 4th at 02:30 PM PT at

  • GlobeNewswire

    Cingulate Announces Closing of $4.0 Million Public Offering

    KANSAS CITY, Kan., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the closing of its previously announced public offering of an aggregate of 6,925,208 shares of its common stock (or common stock equivalents in lieu ther

  • GlobeNewswire

    Cingulate Announces Pricing of $4.0 Million Public Offering

    KANSAS CITY, Kan., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the pricing of its public offering of an aggregate of 6,925,208 shares of its common stock (or common stock equivalents in lieu thereof), Series A warran